Tesis

Perbandingan efek injeksi intravitreal triamsinolon asetonid 4mg dan bevacizumb 1,25mg terhadap ketebalan makula sentral pada edema makular diabetik tipe kistoid dan difus = Comparison of intravitreal triamcinolone acetonide 4mg versus bevacizumad 1,25mg as treatment in cystoid and diffuse type diabetic macular edema.

Tujuan Untuk membandingkan efektivitas intravitreal triamcinolone acetonide (IVTA) dan Bevacizumab (IVB) dalam mengurangi ketebalan makula sentral (CMT) pada edema makular diabetik (EMD) tipe kistoid dan difus Metode Studi ini adalah sebuah uji klinis acak tersamar tunggal. Sebanyak 24 subyek (28 mata) dengan non-proliferatif diabetic retinopathy (NPDR) yang belum pernah menerima terapi apapun sebelumnya akan dibagi menjadi 2 kelompok berdasarkan gambaran OCT, yaitu tipe difus dan kistoid. Subyek dalam setiap kelompok akan diacak untuk menerima IVTA atau IVB. Evaluasi akan dilakukan pada 1 hari, 1 minggu dan 2 minggu setelah injeksi. Penilaian perubahan ketebalan makula sentral (KMS) akan dinilai dengan Optical Coherence Tomography (OCT) lagi pada minggu pertama dan minggu kedua. Hasil Penurunan KMS kelompok kistoid setelah injeksi IVTA dan IVB berbeda secara signifikan dengan p 0,05), namun penurunan tersebut secara klinis kami nilai signifikan berdasarkan hasil OCT (KMS 1 minggu setelah injeksi adalah 111,57 ± 49,72 vs 32,43 ± 37,23 dan 2 minggu setelah injeksi 135,86 ± 68.42 vs 31.86 ± 35.96) Kesimpulan Injeksi intravitreal triamcinolone acetonide merupakan terapi yang lebih tepat untuk edema makula diabetik tipe kistoid
Kata kunci Intravitreal, triamcinolone acetonide, Bevacizumab, DME, difus, cystoid


Objectives To compare the effectiveness of intravitreal Triamcinolone Acetonide (IVTA) and Bevacizumab (IVB) in reducing central macular thickness (CMT) of diffuse type and cystoid type diabetic macular edema (DME) Methods This is a prospective, single blind, randomized clinical trial. A total of 24 subjects (28 eyes) with non-proliferative diabetic retinopathy who had never received any prior therapy, was divided into 2 groups based on the description of the Optical Coherence Tomography (OCT) to differentiate the type of diffuse and cystoid. Subjects in each group were randomized to receive IVTA or IVB. Follow up was conducted at day 1, week 1 and week 2 after injection. CMT were reassesed with OCT on follow up week 1 and week 2. Result CMT decrease in the cystoid group after IVTA and IVB were significantly different with p0.05 ) in CMT decrease between IVTA and IVB, but the decrease were still clinically significant in our OCT findings (in week 1 CMT were 111.57±49.72 vs 32.43±37.23 and in week 2 were 135.86 ±68.42 vs 31.86±35.96) Conclusion Intravitreal injection of triamcinolone acetonide is more proper therapy for cystoid type diabetic macular edema.
Keywords Intravitreal, Triamcinolone Acetonide, Bevacizumab, DME, diffuse type, cystoid type